Gilead Sciences and Genesis Therapeutics Collaborate on AI-Driven Small Molecule Drug Discovery

Partnership Overview:
Gilead Sciences has partnered with Genesis Therapeutics to discover and develop novel small molecule therapies using AI.

AI Platform:
Genesis will utilize its AI platform, Genesis Exploration of Molecular Space (GEMS), to generate and optimize molecules for targets selected by Gilead.

Financial Terms:
Genesis will receive an upfront payment of $35 million for three targets, with options for Gilead to nominate additional targets for a fee. Genesis is also eligible for milestone payments and tiered royalties on net sales.

Collaboration Focus:
The partnership will focus on preclinical research, with Gilead holding exclusive rights for clinical development and potential commercialization of the compounds developed.

Genesis Background:
Genesis Therapeutics has raised over $300 million in funding to build a pipeline targeting high-impact medical conditions.

Gilead’s Perspective:
Gilead believes that the use of generative AI in drug development can accelerate the discovery of molecules for challenging targets, addressing significant unmet patient needs.